Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence

Helgi Thor Hjartarson(Karolinska University Hospital), Thomas Sejersen(Hong Kong Science and Technology Parks Corporation)
Drug Design Development and Therapy
June 1, 2022
Cited by 57


Related Papers